Display options
Cite
Ramanathan RK, Weiss GJ, Posner RG, et al. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol. 2017;8(6):925-935doi: 10.21037/jgo.2017.09.05.
Ramanathan, R. K., Weiss, G. J., Posner, R. G., Rajeshkumar, N. V., Jameson, G., Aziz, M., Hoering, A., Bolejack, V., Maitra, A., Fulk, M., Stites, E. C., Hlavacek, W. S., Gatalica, Z., Xiu, J., Hidalgo, M., Von Hoff, D. D., & Barrett, M. T. (2017). A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Journal of gastrointestinal oncology, 8(6), 925-935. https://doi.org/10.21037/jgo.2017.09.05
Ramanathan, Ramesh K, et al. "A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients." Journal of gastrointestinal oncology vol. 8,6 (2017): 925-935. doi: https://doi.org/10.21037/jgo.2017.09.05
Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05. PMID: 29299351; PMCID: PMC5750179.
Copy Download .nbib Format: NLM
Share it on

J Gastrointest Oncol. 2017 Dec;8(6):925-935. doi: 10.21037/jgo.2017.09.05.

A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients.

Journal of gastrointestinal oncology

Ramesh K Ramanathan, Glen J Weiss, Richard G Posner, N V Rajeshkumar, Gayle Jameson, Meraj Aziz, Antje Hoering, Vanessa Bolejack, Anirban Maitra, Monica Fulk, Edward C Stites, William S Hlavacek, Zoran Gatalica, Joanne Xiu, Manuel Hidalgo, Daniel D Von Hoff, Michael T Barrett

Affiliations

  1. Honor Health Research Institute, Scottsdale, AZ, USA.
  2. Mayo Clinic Cancer Center, Phoenix, AZ, USA.
  3. Translational Genomics Research Institute, Phoenix, AZ, USA.
  4. Department of Oncology and Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  5. Human Therapeutics Division, Intrexon Corporation, Germantown, MD, USA.
  6. Cancer Research And Biostatistics(CRAB), Seattle, WA, USA.
  7. Sheikh Ahmed Pancreatic Cancer Research Center, UT MD Anderson Cancer Center, Houston, TX, USA.
  8. Caris Life Sciences, Phoenix, AZ, USA.
  9. Beth Israel Deaconess Medical Center, Boston, MA, USA.
  10. Centro Nacional de Investigaciones Oncológicas and Hospital de Madrid, Madrid, Spain.

PMID: 29299351 PMCID: PMC5750179 DOI: 10.21037/jgo.2017.09.05

Abstract

BACKGROUND: The choice of a regimen in metastatic pancreatic cancer patients following progression on 1st line therapy is empiric and outcomes are unsatisfactory. This phase II study was performed to evaluate the efficacy of therapy selected by immunohistochemistry (IHC) in these patients following progression after one or more therapies.

METHODS: Eligible patients underwent a percutaneous biopsy of a metastatic lesion and treatment selection was determined by IHC. The study required 35 evaluable patients (power of 86%) for detecting a true 1-year survival rate of >20%.

RESULTS: A tumor biopsy was performed in 48 of 49 accrued patients. Study therapy was not given (n=13) either due to insufficient tumor on biopsy (n=8) or due to worsening cancer related symptoms after biopsy (n=5). The demographics of evaluable patients (n=35) are male/female (59%/41%), with age range 34-78 years (median 63 years). Patients had 1-6 prior regimens (median of 2). The most common IHC targets were topoisomerase 1 or 2, thymidylate synthase, excision repair cross-complementation group 1 protein (ERCC1), and osteonectin secreted protein acidic and rich in cysteine (SPARC). Commercially available treatment regimens prescribed included FOLFIRI, FOLFOX, irinotecan, and doxorubicin. The response (RECIST) was 9%, the median survival was 5.6 months (94% CI, 3.8-8.2), and the 1-year survival was 20% (95% CI, 7-33%).

CONCLUSIONS: In all patients, IHC assays resulted in identification of at least two targets for therapy and a non-cross resistant regimen could be prescribed for therapy with evidence of some benefit. An IHC based treatment strategy is feasible and needs validation in larger studies.

Keywords: Array comparative genomic hybridization (aCGH); immunohistochemistry (IHC); molecular profiling (MP); pancreatic cancer; phase II clinical trial

Conflict of interest statement

Conflicts of Interest: This work was presented in part at the American Association for Cancer Research; 103rd Annual Meeting (LB-221 and A 3697), 2012, Chicago, IL, USA. RK Ramanathan: meeting honorar

References

  1. Cancer Chemother Pharmacol. 2012 Jun;69(6):1641-5 - PubMed
  2. J Clin Oncol. 2008 Jun 1;26(16):2690-8 - PubMed
  3. J Clin Oncol. 2016 Nov 10;34(32):3914-3920 - PubMed
  4. J Clin Oncol. 2016 Aug 10;34(23 ):2784-96 - PubMed
  5. N Engl J Med. 2011 May 12;364(19):1817-25 - PubMed
  6. Int J Cancer. 2008 Nov 15;123(10):2384-9 - PubMed
  7. Am J Clin Oncol. 2013 Apr;36(2):151-6 - PubMed
  8. N Engl J Med. 2013 Oct 31;369(18):1691-703 - PubMed
  9. Clin Cancer Res. 2003 Sep 15;9(11):4165-71 - PubMed
  10. J Comput Biol. 2006 Mar;13(2):215-28 - PubMed
  11. J Clin Oncol. 2010 Nov 20;28(33):4877-83 - PubMed
  12. Eur J Cancer. 2011 Jun;47(9):1319-27 - PubMed
  13. Br J Cancer. 2013 Apr 2;108(6):1238-44 - PubMed
  14. Clin Cancer Res. 2003 Mar;9(3):1136-44 - PubMed
  15. J Clin Oncol. 2014 Aug 10;32(23):2423-9 - PubMed
  16. Eur J Cancer. 2009 Jan;45(2):228-47 - PubMed
  17. World J Gastroenterol. 2012 Mar 28;18(12):1357-64 - PubMed
  18. Rev Recent Clin Trials. 2010 Jan;5(1):43-56 - PubMed
  19. Breast Cancer Res Treat. 2011 Jul;128(2):401-9 - PubMed
  20. Breast Cancer Res Treat. 2014 Oct;147(3):579-88 - PubMed
  21. Lancet. 2016 Feb 6;387(10018):545-57 - PubMed
  22. N Engl J Med. 2013 Mar 21;368(12):1101-10 - PubMed
  23. PLoS One. 2012;7(11):e50586 - PubMed
  24. Mol Cancer Ther. 2011 Aug;10(8):1311-6 - PubMed
  25. Anticancer Res. 2010 Oct;30(10):4289-95 - PubMed
  26. Oncology. 2009;76(4):270-4 - PubMed
  27. Br J Cancer. 2017 Aug 8;117(4):572-582 - PubMed
  28. J Clin Oncol. 2011 Dec 1;29(34):4548-54 - PubMed
  29. Cancer Chemother Pharmacol. 2012 Feb;69(2):425-30 - PubMed
  30. Br J Cancer. 2009 Nov 17;101(10 ):1658-63 - PubMed
  31. Cancer Chemother Pharmacol. 2011 Sep;68(3):743-51 - PubMed
  32. Clin Cancer Res. 2014 Oct 15;20(20):5281-9 - PubMed
  33. Clin Cancer Res. 2015 Nov 1;21(21):4811-8 - PubMed
  34. Crit Rev Oncol Hematol. 2017 Jul;115:1-12 - PubMed
  35. Nat Rev Cancer. 2002 Jan;2(1):48-58 - PubMed

Publication Types